USP <88> has historically carried outsized weight in pharmaceutical packaging programs. For years, references to “USP <88> compliance” or “Class VI materials” were treated as shorthand for biocompatibility, often without careful consideration of exposure, material function, or patient risk.

The revised USP <88> fundamentally changes that paradigm. Rather than serving as a broad biological classification system, USP <88> is now deliberately narrow in scope and intent. Understanding this change is critical for packaging teams seeking to modernize their programs, reduce unnecessary animal testing, and avoid avoidable cost and timeline impacts as 2026 approaches.

From Broad Classification to Targeted Problem-Solving

Historically, USP <88> encompassed multiple in vivo tests and was frequently applied as a default requirement. In practice, this meant materials were escalated to animal testing simply because specifications required it, not because unresolved biological risk existed.

Revised USP <88> removes much of that ambiguity. The chapter now focuses primarily on the Systemic Injection Test and positions in vivo testing as a **conditional tool**, not a screening step. This change aligns USP <88> with modern regulatory expectations that animal testing be used intentionally and only when it adds meaningful scientific value.

What USP <88> Is Intended to Address Today

Under the revised framework, USP <88> applies primarily to **elastomeric components** used in pharmaceutical packaging, and only when lower-tier data cannot adequately address biological risk.

This distinction matters. Elastomers may contain additives, curing agents, or processing residues that warrant closer scrutiny under certain conditions. However, even for elastomers, USP <88> is not automatically required. Its application depends on what is already known from in vitro screening, chemical characterization, and toxicological assessment.

Plastics, oral packaging, and topical packaging systems are generally outside the intended scope of USP <88> unless there is a clear scientific justification tied to exposure.

USP <88> Within a USP <1031>-Aligned Strategy

USP <1031> provides the decision framework that governs when USP <88> should be considered. Within this framework, biological evaluation progresses in tiers:

First, in vitro screening under USP <87> is used to identify overt biological reactivity.
Second, chemical characterization defines what substances may migrate into the drug product.
Third, toxicological risk assessment evaluates whether identified substances pose patient risk at expected exposure levels.

Only when these steps leave unresolved uncertainty does USP <1031> support escalation to in vivo testing under USP <88>. This tiered logic is explicit and intentional.

Common Misapplications of USP <88>

As organizations transition to the revised chapters, several recurring misapplications of USP <88> continue to appear:

  • Treating USP <88> as a default requirement for all packaging materials
    • Applying USP <88> based on legacy Class VI references rather than exposure
    • Using USP <88> to compensate for gaps in chemical or toxicological data
    • Running USP <88> late in development, when remediation options are limited

Each of these practices increases cost and animal testing without improving patient safety.

Ethical, Scientific, and Operational Implications

The reframing of USP <88> reflects not only scientific progress but also ethical responsibility. Regulators and standards bodies increasingly expect that animal testing be minimized when alternative methods can adequately address risk.

From an operational standpoint, unnecessary USP <88> testing introduces significant challenges:
– Long lead times driven by limited in vivo capacity
– Higher direct testing costs
– Delays during change control or supplier transitions
– Increased scrutiny during audits when justification is weak

Reducing reliance on USP <88> through proper use of USP <87>, chemistry, and toxicology improves both compliance and efficiency.

Preparing for December, 2026 Without Overcorrecting

As the December 1, 2026 effective date approaches, some organizations are reacting by planning broad re-testing campaigns. In many cases, this response is unnecessary and counterproductive.

A modern, USP <1031>-aligned strategy focuses on identifying where true uncertainty exists, and where it does not. By doing so, packaging teams can reserve USP <88> for the limited scenarios where it adds value, while confidently omitting it elsewhere.

The Bottom Line

Revised USP <88> does not eliminate in vivo testing, nor does it diminish its importance when warranted. Instead, it restores proportionality.

For pharmaceutical packaging teams, the message is clear: USP <88> is no longer a default checkbox. It is a targeted, conditional tool: one that should be applied thoughtfully, documented carefully, and used only when it meaningfully advances patient safety.

Understanding and applying this reframed intent will be critical for organizations seeking to control cost, timelines, and regulatory risk in the years ahead